Anixa Biosciences’ (ANIX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a report published on Monday, Benzinga reports. They currently have a $12.00 target price on the stock.

Separately, TheStreet downgraded shares of Anixa Biosciences from a c- rating to a d rating in a report on Friday, June 16th.

Anixa Biosciences Price Performance

ANIX stock opened at $3.38 on Monday. The firm has a market capitalization of $105.02 million, a P/E ratio of -9.66 and a beta of 0.94. Anixa Biosciences has a 52-week low of $2.90 and a 52-week high of $6.45. The company’s 50 day simple moving average is $3.58 and its 200-day simple moving average is $3.80.

Insider Buying and Selling at Anixa Biosciences

In related news, CEO Amit Kumar sold 11,800 shares of the company’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $3.57, for a total transaction of $42,126.00. Following the transaction, the chief executive officer now directly owns 461,925 shares of the company’s stock, valued at approximately $1,649,072.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 20.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Anixa Biosciences

Several institutional investors have recently modified their holdings of ANIX. UBS Group AG boosted its holdings in Anixa Biosciences by 2.6% during the first quarter. UBS Group AG now owns 638,996 shares of the company’s stock worth $2,748,000 after buying an additional 16,452 shares in the last quarter. Geode Capital Management LLC increased its holdings in Anixa Biosciences by 10.5% in the 2nd quarter. Geode Capital Management LLC now owns 303,018 shares of the company’s stock valued at $970,000 after buying an additional 28,729 shares during the period. BlackRock Inc. grew its holdings in Anixa Biosciences by 191.9% during the 3rd quarter. BlackRock Inc. now owns 297,513 shares of the company’s stock worth $1,464,000 after acquiring an additional 195,603 shares during the last quarter. Susquehanna International Group LLP raised its holdings in Anixa Biosciences by 73.4% during the first quarter. Susquehanna International Group LLP now owns 155,784 shares of the company’s stock worth $670,000 after buying an additional 65,961 shares during the last quarter. Finally, State Street Corp lifted its holdings in Anixa Biosciences by 12.3% during the first quarter. State Street Corp now owns 102,100 shares of the company’s stock valued at $280,000 after purchasing an additional 11,213 shares during the last quarter. Hedge funds and other institutional investors own 11.78% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus.